Skip to main content

Table 3 Summary scores (baseline) and change scores for primary and secondary outcome variables.

From: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

  Quetiapine Placebo
YBOCS (baseline) 26.4 (SD4.6) 27.7(SD3.9)
YBOCS (change at week 6) -7.1(SD7.2) -7.2(SD8.4)
YBOCS % change -26.9% -26%
CGI-Severity (baseline) 5.2 (SD0.8) 5.3 (SD0.8)
CGI-Severity (week 6) 4.1 (SD1.4) 4.1(SD1.5)
MADRS (baseline) 10.6 (SD 4.8) 10.71 (SD 9.8)
MADRS (change at week 6) -2.6 (SD 6.5) -3 (SD 8.3)
SDS (baseline) 17.9 (SD 5.3) 19.6(SD4.7)
SDS (change at week 6) -5.3(SD5.6) -6.1 (SD4.8)
YGTSS (baseline) 24.7 (SD 19.3) 22.6(SD 22.3)
YGTSS (change at week 6) -4.5(SD 5.1) -9.4 (SD 14.6)
YGTSS % change -18.2% -41.6%